Aldeyra Therapeutics, Inc. (ALDX)
Automate Your Wheel Strategy on ALDX
With Tiblio's Option Bot, you can configure your own wheel strategy including ALDX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowNews
Shareholders who lost money in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) Should Contact Wolf Haldenstein Immediately
Published: April 03, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP informs investors that a securities fraud class action lawsuit has been filed against Aldeyra Therapeutics, Inc., (“Aldeyra” or the "Company") (NASDAQ: ALDX) on behalf of investors that bought securities between November 3, 2023 and March 16, 2026, inclusive (the “Class Period”). Investors have until May 29, 2026 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Read More
ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: April 03, 2026 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, April 03, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aldeyra Therapeutics, Inc. (“Aldeyra” or “the Company”) (NASDAQ: ALDX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between November 3, 2023, and March 16, 2026, inclusive (the “Class Period”), are encouraged to contact the firm before May 29, 2026.
Read More
ALDX INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026
Published: April 03, 2026 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aldeyra To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Aldeyra between November 3, 2023 and March 16, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, April 3, 2026 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") …
Read More
ALDX SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026
Published: April 02, 2026 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aldeyra To Contact Him Directly To Discuss Their Options
Read More
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ALDX
Published: April 01, 2026 by: Newsfile Corp
Sentiment: Neutral
New York, New York--(Newsfile Corp. - April 1, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) between November 3, 2023 and March 16, 2026, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed.
Read More
Bronstein, Gewirtz & Grossman LLC Urges Aldeyra Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Published: April 01, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, April 01, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Aldeyra securities between November 3, 2023 and March 16, 2026, both dates inclusive (the “Class Period”).
Read More
Portnoy Law Firm Announces Class Action on Behalf of Aldeyra Therapeutics, Inc. Investors
Published: March 31, 2026 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, March 31, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Aldeyra Therapeutics, Inc., (“Aldeyra” or the "Company") (NASDAQ: ALDX) investors of a class action on behalf of investors that bought securities between November 3, 2023 and March 16, 2026, inclusive (the “Class Period”). Aldeyra investors have until May 29, 2026 to file a lead plaintiff motion.
Read More
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Aldeyra Therapeutics, Inc. (ALDX)
Published: March 31, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the District of Massachusetts on behalf of all persons or entities who purchased or otherwise acquired Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) (NASDAQ: ALDX) securities between November 3, 2023 and March 16, 2026, inclusive (the “Class Period”).
Read More
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - ALDX
Published: March 23, 2026 by: Newsfile Corp
Sentiment: Neutral
New York, New York--(Newsfile Corp. - March 23, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) resulting from allegations that Aldeyra may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Aldeyra securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
Potential Securities Fraud: Levi & Korsinsky Investigates Aldeyra Therapeutics, Inc. (ALDX)
Published: March 18, 2026 by: Newsfile Corp
Sentiment: Neutral
New York, New York--(Newsfile Corp. - March 18, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Aldeyra Therapeutics, Inc. ("Aldeyra Therapeutics, Inc.") (NASDAQ: ALDX) concerning potential violations of the federal securities laws. Throughout 2024 and 2025, Aldeyra's made forward-looking statements regarding the development and regulatory prospects of reproxalap for the treatment of dry eye disease.
Read More
ALDX Crashes 71% as FDA Issues Third CRL for Dry Eye Disease Drug NDA
Published: March 18, 2026 by: Zacks Investment Research
Sentiment: Negative
Aldeyra Therapeutics stock plunges 71% after the FDA issues a third CRL for the resubmitted reproxalap NDA for the treatment of dry eye disease.
Read More
Is Aldeyra Therapeutics (ALDX) Outperforming Other Medical Stocks This Year?
Published: February 26, 2026 by: Zacks Investment Research
Sentiment: Positive
Here is how Aldeyra Therapeutics, Inc. (ALDX) and Iovance Biotherapeutics (IOVA) have performed compared to their sector so far this year.
Read More
Does Aldeyra Therapeutics (ALDX) Have the Potential to Rally 79.28% as Wall Street Analysts Expect?
Published: February 19, 2026 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 79.3% upside potential for Aldeyra Therapeutics (ALDX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
Wall Street Analysts Predict a 65.75% Upside in Aldeyra Therapeutics (ALDX): Here's What You Should Know
Published: February 03, 2026 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 65.8% upside potential for Aldeyra Therapeutics (ALDX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
Are Medical Stocks Lagging Aldeyra Therapeutics (ALDX) This Year?
Published: February 03, 2026 by: Zacks Investment Research
Sentiment: Negative
Here is how Aldeyra Therapeutics, Inc. (ALDX) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.
Read More
Aldeyra Therapeutics, Inc. (ALDX) Discusses PDUFA Target Action Date Extension for Reproxalap in Dry Eye Disease Transcript
Published: December 16, 2025 by: Seeking Alpha
Sentiment: Neutral
Aldeyra Therapeutics, Inc. (ALDX) Discusses PDUFA Target Action Date Extension for Reproxalap in Dry Eye Disease Transcript
Read More
Aldeyra Therapeutics, Inc. (ALDX) Discusses Expansion of RASP Platform Into CNS Diseases and Update on Reproxalap for Dry Eye Transcript
Published: November 13, 2025 by: Seeking Alpha
Sentiment: Neutral
Aldeyra Therapeutics, Inc. ( ALDX ) Discusses Expansion of RASP Platform Into CNS Diseases and Update on Reproxalap for Dry Eye November 13, 2025 8:00 AM EST Company Participants Laura Nichols - Operations Manager Todd Brady - CEO, President & Director Adam Lazorchak Conference Call Participants Thomas Shrader - BTIG, LLC, Research Division Catherine Novack - JonesTrading Institutional Services, LLC, Research Division Clara Dong Yale Jen Presentation Operator Hello, and welcome, everyone, to the Aldeyra Therapeutics 2025 Research and Development Update Webcast. My name is Becky, and I'll be your operator today.
Read More
Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease
Published: July 17, 2025 by: Business Wire
Sentiment: Neutral
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmitted New Drug Application (NDA) for topical ocular reproxalap, a first-in-class investigational new drug candidate, for the treatment of the signs and symptoms of dry eye disease. The FDA assigned a Prescription Drug User Fee Act (PDUFA) target action date of December 16, 2025. “Based on the FDA's requirement f.
Read More
5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats
Published: July 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Innovation is at its peak in the Zacks Medical-Drugs industry. CPRX, ZVRA, TBPH, ALDX and LRMR may prove to be good additions to one's portfolio.
Read More
Aldeyra Therapeutics (ALDX) Upgraded to Strong Buy: What Does It Mean for the Stock?
Published: July 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Aldeyra Therapeutics (ALDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Read More
Aldeyra Therapeutics: Pivotal FDA Decision After Reproxalap's Chamber Data
Published: July 02, 2025 by: Seeking Alpha
Sentiment: Positive
Aldeyra Therapeutics' Reproxalap is now on its third NDA, which was filed in June 2025. It supposedly fixes prior trial flaws. ALDX believes a potential FDA acceptance could set a PDUFA date for December 2025. After that, AbbVie may pay $100 million upfront and share US profits if Reproxalap wins approval, which should materially de-risk its eventual commercialization.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX
Published: May 16, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ:ALDX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aldeyra Therapeutics, Inc. – ALDX
Published: May 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) (NASDAQ: ALDX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
ALDX SECURITIES UPDATE: Aldeyra Therapeutics Investors with Losses may have been affected by Securities Violations – Contact BFA Law (NASDAQ:ALDX)
Published: May 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) for potential violations of the federal securities laws. If you invested in Aldeyra Therapeutics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/aldeyra-therapeutics-inc.
Read More
Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response Letter – Hagens Berman
Published: May 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, May 06, 2025 (GLOBE NEWSWIRE) -- On April 3, 2025 investors in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) saw the price of their shares crash over 70% after the company announced that it received a Complete Response Letter (“CRL”) from the FDA for the resubmission of the New Drug Application (“NDA”) of reproxalap, an investigational drug candidate, for the treatment of dry eye disease.
Read More
ALDX SECURITIES NEWS: Aldeyra Therapeutics, Inc. Investigation Could Allow Investors to Recover Losses; Contact BFA Law to Discuss
Published: May 06, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 6, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) for potential violations of the federal securities laws. If you invested in Aldeyra Therapeutics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/aldeyra-therapeutics-inc.
Read More
ALDX SECURITIES NOTICE: Suffer Losses on Aldeyra Therapeutics, Inc.? Investors are Alerted to Contact BFA Law about its Continuing Investigation
Published: May 05, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 5, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) for potential violations of the federal securities laws. If you invested in Aldeyra Therapeutics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/aldeyra-therapeutics-inc.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX
Published: May 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) (NASDAQ: ALDX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX
Published: May 02, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 2, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ:ALDX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
ALDX INVESTIGATION: Aldeyra Therapeutics (NASDAQ:ALDX) Investors with Losses are Urged to Contact BFA Law about its Investigation into the Company
Published: May 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) for potential violations of the federal securities laws. If you invested in Aldeyra Therapeutics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/aldeyra-therapeutics-inc.
Read More
About Aldeyra Therapeutics, Inc. (ALDX)
- IPO Date 2014-05-02
- Website https://www.aldeyra.com
- Industry Biotechnology
- CEO Todd C. Brady
- Employees 9